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Abstract
Aim: The human papillomavirus (HPV) vaccination rate in Japan fell to nearly 0% following widespread
coverage of possible adverse events. Developing a next approach to promote the effective prevention of
HPV-related diseases including cervical cancer (CC) in Japan requires comprehensive understanding of
knowledge and attitudes regarding CC prevention, HPV infection and HPV vaccination among the popula-
tion including laypersons and medical professions in Japan.
Methods: A questionnaire survey was administered in a wide variety of settings in Japan. The questionnaire
contained items on knowledge about CC, HPV infection and HPV vaccination; awareness of the HPV vac-
cine’s effectiveness and associated adverse events; and attitudes toward the HPV vaccination for their
daughters and for men/boys.
Results: Of 3033 targeted people, complete survey responses were received from 1182 men and 1602 women
(total: 2784). The male laypersons’ group had significantly lower knowledge than did the female laypersons’
group (adjusted odds ratio, aOR = 3.86, P < 0.001). Compared with the male laypersons’ group, the female
laypersons’ group tended to have less positive attitudes toward HPV vaccination for their daughters (aOR =
0.78, P = 0.006), but the female laypersons’ group showed more positive attitudes toward vaccinating
men/boys (aOR = 1.93, P < 0.001).
Conclusion: The survey results indicated that men in Japan generally lacked knowledge and awareness of
HPV-related diseases and their prevention. However, women had more negative attitudes toward HPV vac-
cination for their daughters than did men. Increasing male involvement in HPV prevention and changing
women’s perceptions of the HPV vaccine are essential steps to increase the HPV vaccination rate.
Key words: cervical cancer, HPV vaccination, human papillomavirus, male involvement, questionnaire.
Introduction
Human papillomavirus (HPV) causes various types of
diseases, both benign and malignant. Vulvar and
laryngeal papillomas are representative of the benign
diseases caused by HPV. HPV-related cancers include
cervical cancers (CC), as well as vaginal, vulvar, anal,
penile, oropharyngeal and oral cancers. The impor-
tance of primary and secondary prevention of HPV-
related diseases has become a worldwide concern in
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the current decade, not only for women but also
for men.1
The number of CC patients in Japan has gradually
increased. The incidence of CC was estimated at
7868 in 2000, 8474 in 2005, 10 737 in 2010 and 10 520
in 2013.2 In this context, it was necessary to promote
a CC prevention program as soon as possible. In
October 2009, the Japan Society of Obstetrics and
Gynecology strongly recommended HPV vaccination
for girls aged 11–14 years.3 The Japanese Ministry of
Health, Labour and Welfare (MHLW) began an HPV
vaccination program for young girls, with financial
support, in 2011, and the Ministry’s formal national
HPV vaccine program began in April 2013.4 The pro-
gram has continued since then; however, only
3 months after the program’s initiation, in June 2013,
the MHLW suspended its recommendation of HPV
vaccination because of widespread public suspicion
of adverse events, especially chronic general pain
and/or motor disorder after receiving the vaccina-
tion. This situation has been projected to cause an
enormous negative future impact on the prevention
of CC and HPV-related diseases in Japan.4 It was
also reported that 186 women (0.005% of all of those
vaccinated) had not recovered from the adverse
events at the time of a national investigation in
2015.5 Most of the adverse events were considered to
be caused by functional somatic syndrome. These
cases were reported repeatedly and widely in the
media, including television, radio, newspapers and
magazines, as adverse reactions. As a result of this
media coverage, many Japanese people began to feel
anxiety and distrust toward the HPV vaccine. In a
recent study, symptoms similar to those that were
thought to be adverse events were observed in par-
ticipants irrespective of HPV vaccination status.6
Furthermore, other researchers have demonstrated
that there has been no significant increase in the
occurrence of any of the 24 reported post-HPV vacci-
nation symptoms.7 Nevertheless, the proactive rec-
ommendation for the national HPV vaccine program
has yet to be reissued.
To construct an appropriate strategy for improving
the prevention of HPV-related diseases in Japan, we
need to know the current state of knowledge and atti-
tudes regarding HPV-related disease prevention. We
sought to investigate and clarify attitudes toward CC
prevention, HPV infection and HPV vaccination
among the general population. In addition, we aimed
to test our hypothesis that men in Japan would be
indifferent to HPV infection and CC.
Methods
Participants and settings
We conducted our study from October 2015 to June
2016 in various settings. In total, the study was con-
ducted in 21 locations, including public spaces, class-
rooms, company offices, university festivals, citizens’
open forums and an academic meeting. We recruited
male and female participants aged over 16 years to
complete a questionnaire after providing their con-
sent. We explained the questionnaire survey verbally
and used printed information for those who attended
the meetings and events. We confirmed participants’
submission of the completed questionnaire, including
the provision of consent. A street survey was con-
ducted in the public events space at Yokohama Sta-
tion on Wednesday, May 18, 2016 and Sunday, June
12, 2016. Classroom surveys of the following groups
were also conducted: fifth-year students at Yokohama
City University Medical School, first- and second-year
students in the Kanagawa University Faculty of
Human Sciences, third-year students in the Interna-
tional College of Arts and Sciences at Yokohama City
University, and the general student bodies of three
nursing schools in Tokyo Prefecture, Saitama Prefec-
ture and Niigata Prefecture. Seven cooperating com-
panies were selected based on the following three
criteria: having at least 10 employees, being located in
Yokohama City, and giving consent by phone, e-mail
and/or visitation. Furthermore, questionnaires were
administered at various locations and in multiple situ-
ations, such as a medical college festival at Yokohama
City University; four citizens’ open forums in the cit-
ies of Yokohama, Osaka and Niigata; and a cytology
conference in Kanagawa Prefecture.
Questionnaire
A questionnaire to measure attitudes and knowledge
regarding CC, HPV and HPV vaccination was created
based on existing questionnaire surveys,8–12 including
a previous study conducted by our research group.
We adopted a ready-made scoring sheet, SN-0289
(SCANET Co., Ltd). The questionnaire included a
total of 11 items assessing knowledge: 6 questions
about CC, 3 questions about HPV infection and
2 questions about HPV vaccination. These 11 items
consisted of 8 true–false statements and 3 multiple-
choice questions. We explained how to fill in the
questionnaire to participants verbally, but once they
began to record their answers we did not intervene.
To measure awareness of the effectiveness and
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adverse events associated with HPV vaccination, the
following questions were incorporated: ‘Are you
aware of any positive effects of the HPV vaccine?’
and ‘Are you aware of any adverse events associated
with the HPV vaccine?’ The following questions mea-
sured motivation to undergo HPV vaccination: ‘If you
have/had a daughter, do/would you want her to
be vaccinated against HPV?’ and ‘Do you think
men/boys should be vaccinated against HPV?’
The questionnaire also included items on demo-
graphic characteristics such as sex (male, female), pro-
fession, age, marital status (married, unmarried),
sexual experience (experienced, not experienced,
declined to answer), time since the last Papanicolaou
smear (never, <2, 2–5, >5 years, unknown) and HPV
vaccination status (already vaccinated, not yet vacci-
nated, unknown). The questions about last Papanico-
laou smear and HPV vaccination status were
answered only by female participants. Participants
were able to choose from the following 17 professions:
(1) medical school student; (2) nursing school student;
(3) other medical student; (4) nonmedical college/uni-
versity student; (5) high school student; (6) other stu-
dent; (7) medical doctor; (8) nurse, public health
nurse, and/or midwife; (9) pharmacist; (10) medical
laboratory technician; (11) other medical professional;
(12) office worker; (13) teacher; (14) civil servant;
(15) stay at home spouse; (16) part time worker or
(17) other. Professions 1–3 and 7–11 were categorized
as the medical profession group. Other professions
were defined as the laypersons’ group.
Participants filled out a 20-question, multiple-
choice, anonymous questionnaire. Completing the
survey took approximately 5–10 min. Eleven ques-
tions regarding knowledge were scored and divided
into three groups by tertiles: low (0–4 points),
medium (5–7 points) and high (8–11 points).
Statistics
The statistical analysis was performed using Student’s
t-test, the χ2 test, and binominal logistic regression
analysis. Odds ratios and age-, marital-status-, sex-
experience- and sex-adjusted odds ratios (aOR) from
the binominal logistic regression were analyzed to
assess differences in knowledge and attitudes among
four subgroups: male laypersons, female laypersons,
male medical professionals and female medical pro-
fessionals. Age (categorized into the following age
groups: 16–19, 20–29, 30–39, 40–49, 50–59 and
≥60 years), marital status, and sexual experience were
included as covariates in the subgroup analysis
conducted using binominal logistic regression. Sex
was added as a covariate in the analysis of the knowl-
edge level groups. Values of P < 0.05 were defined as
significant. All statistical analyses were performed
using SPSS, version 22 (IBM Corporation).
Ethics approval
This study protocol was approved by the Institutional
Ethics Committee of Yokohama City University
School of Medicine.
Results
Recruitment
We administered the questionnaire survey on 21 occa-
sions, resulting in a total of 3033 returned question-
naires. Of these, 249 questionnaires with missing
information on age, sex and/or profession were
excluded from the analysis. The details of each group
of questionnaire surveys are shown in Table 1. We
collected a large number of responses, especially in
classrooms, companies and public spaces. The sample
size for the classroom survey was as follows: 68 in a
medical school, 314 in three nursing schools and
447 in two other universities.
Characteristics
Characteristics of the participants are shown in
Table 2. A total of 2784 participants were analyzed,
Table 1 Number of questionnaires collected at various
settings (on 21 occasions)
Setting Number of
locations
Number of
questionnaires
collected
Classroom 6 829
Company 7 815
Public space
(Yokohama
Station)
2 755
University
festival at
medical school
1 307
Citizens’ open
forum
4 237
Academic
meeting
1 90
Total 21 3033
Appropriate for
analysis
2784
Inappropriate† 249
†Questionnaires without answers for age, sex and/or
profession.
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including 1182 men and 1602 women. The age distri-
bution was different for men and women (P = 0.004):
The proportion in their 40s was higher for women
than for men (21.5% vs 17.8%), and the proportion in
their 50s was significantly higher for men than for
women (16.0% vs 11.9%). The proportion of medical
professionals was 13.5% for men and 29.2% for
women. Overall, the proportion of participants in
medical professions was 22.6%, and the proportion
of participants in nonmedical professions (layper-
sons) was significantly higher, at 77.4% (P < 0.001).
The proportion who were married was higher for
men than for women (P < 0.001). About 67% of
women aged over 20 years had undergone a Papani-
colaou test of the cervix. The HPV vaccination rate
among women was 33.5% in those in their teens
or 20s.
Participants’ knowledge of HPV, CC and
prevention
The correct answer rates for each question gauging
knowledge of CC screening, HPV and HPV vaccina-
tion are shown in Figure 1. For all 11 questions,
women had significantly higher correct answer
rates than did men (P < 0.001), and medical profes-
sionals had significantly higher correct answer rates
than did laypersons (P < 0.001). The correct answer
rates for individual questions among all partici-
pants ranged from 7.2% (Question 9) to 82.9%
(Question 1).
Knowledge levels among the groups are shown in
Table 3. In the medical group, there were no differ-
ences in knowledge level between male and female
participants (P = 0.302), whereas, in the laypersons’
group, women had a significantly higher overall
knowledge level than did men (P < 0.001). The three
subgroups of female laypersons, male medical profes-
sionals and female medical professionals had signifi-
cantly higher knowledge levels than did the male
laypersons’ group (aOR = 3.86, 16.73 and 18.06,
respectively).
Awareness of the effectiveness and adverse
events associated with the HPV vaccine
The results for awareness of the effectiveness of HPV
vaccination and postvaccination adverse events are
shown in Table 4. Awareness of the effectiveness of
the vaccine was significantly higher in the female lay-
persons’ group than in the male laypersons’ group
(aOR = 2.45, P < 0.001). Awareness of the effective-
ness was significantly higher in male professionals
(aOR = 5.29, P < 0.001) and female medical profes-
sionals (aOR = 6.47, P < 0.001) than in the male lay-
persons’ group. Comparing knowledge levels, the
high knowledge level group had a significantly higher
awareness of the effectiveness of the vaccine than did
the low knowledge level group (aOR = 9.64,
P < 0.001).
Awareness of adverse events after HPV vaccination
was significantly higher in the female laypersons’
group than in the male laypersons’ group (aOR =
3.93, P < 0.001). Awareness of adverse events was
significantly higher in male professionals (aOR = 6.55,
P < 0.001) and female medical professionals (aOR =
14.38, P < 0.001) than in the male laypersons’ group.
Comparing knowledge levels, the high knowledge
level group had a significantly higher awareness of
adverse events than did the low knowledge level
group (aOR = 14.62, P < 0.001).
Attitudes toward HPV vaccination
About half of all participants were undecided with
regard to a stance on HPV vaccination for their real
or hypothetical daughters or for boys and men
(Table 5). However, the female laypersons’ group
tended to have less positive attitudes toward HPV
vaccination for their real or hypothetical daughters,
compared with the male laypersons’ group (aOR =
0.78, P = 0.006). In contrast to their negative attitudes
toward HPV vaccination for their real or hypothetical
daughters, the female laypersons’ group showed the
most positive attitudes toward vaccinating boys and
men (aOR = 1.93, P < 0.001). Comparing knowledge
levels, attitudes toward vaccinating real or hypotheti-
cal daughters were significantly more positive in the
high knowledge level group than in the low knowl-
edge level group (aOR = 2.66, P < 0.001). These
groups’ attitudes toward vaccinating boys and men
were similar to their attitudes toward vaccinating
their own daughters.
Discussion
To our knowledge, this is the largest questionnaire
survey study including male participants to investi-
gate knowledge and attitudes regarding CC preven-
tion, HPV and HPV vaccination among Japanese
people. As expected, the present study revealed that
the Japanese population in general—and especially
males in nonmedical professions—had low levels of
knowledge and awareness of HPV and HPV
998 © 2019 Japan Society of Obstetrics and Gynecology
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vaccination. Awareness of adverse events after HPV
vaccination was clearly higher than awareness of the
vaccine’s effectiveness, and this was assumed to be
because of the influence of the mass media in Japan
(e.g., TV reports, newspapers and magazines).4,13 The
HPV vaccine is referred to as a ‘cervical cancer pre-
ventive vaccine’ in Japan, and this is considered one
of the reasons that Japanese men tend to think that
the HPV vaccine and CC are not related to them per-
sonally. This situation is one of the major obstacles to
achieving high HPV vaccination rates in Japan, in line
with those in other parts of the developed world.14
We have launched a new website that provides easy-
to-understand information on scientific journals and
Figure 1 Comparison of the correct answer rate for knowledge of cervical cancer (CC) screening, HPV and HPV vaccina-
tion by sex and profession (medical vs nonmedical laypersons) (N = 2784). Q1 (TRUE): The cost of CC screening is sub-
sidized by local governments in Japan. Q2 (FALSE): HPV vaccine inoculation eliminates the need for CC screening. Q3
(TRUE): CC screening is a test to examine cells obtained by rubbing the cervix. Q4 (TRUE): It is possible to find both
cancer and pre-cancerous lesions through CC screening. Q5 (FALSE): CC screening is unnecessary for women in their
20s with sexual experience. Q6 (around 40%): What is the CC screening rate over the past 2 years among women aged
20–69 years in Japan? Q7 (TRUE): Sexual experience is associated with carcinogenic HPV infection. Q8 (FALSE): If you
use a condom during sexual intercourse, HPV infection can be prevented. Q9 (above 61%): What is the lifetime infection
rate of carcinogenic HPV? Q10 (10s): In which generation is HPV vaccination most effective? Q11 (FALSE): At present
in Japan, subsidies are unavailable for HPV vaccination. † Number of correct answers. The horizontal line for each scale
indicates the 95% confidence interval.
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topics (http://kanagawacc.jp/) in Japanese to intro-
duce important scientific facts.
Although a number of questionnaire surveys have
been conducted to investigate knowledge and atti-
tudes toward HPV prevention, selection bias tends to
be a problem because of the types of target groups
used for recruitment, such as Internet users,8 new
female college students9 and a university-hospital-
based community.10 In the present survey, we
planned to obtain data from people from diverse gen-
erations and professions to the extent possible to
reduce such selection bias. To achieve this, we col-
lected questionnaires from the various companies and
carried out events in a public space (Yokohama Sta-
tion), with support from several volunteers, including
a CC survivor. We provided leaflets about general
cancer prevention and small low-priced gifts
(e.g., handkerchiefs, sweets, drinks or toys), mainly
for the participants with children, to recruit as many
representatives of the general population as possible.
In this way, we sought to recruit participants who did
not have a particular interest in cancer prevention
and/or health issues.
Although several questionnaire surveys about HPV
prevention among Japanese mothers have been
reported,13 these previous studies did not include
questions about male involvement in HPV prevention
or about whether boys and men should also be vacci-
nated, and only a few surveys researching the aware-
ness of HPV prevention have focused on
men.11,12,15,16 A study that targeted 27 fathers living
in Japan found that they had poor knowledge but a
high acceptance of HPV vaccination,15 similar to our
findings. The authors of this previous work stressed
the importance of active male involvement in CC pre-
vention strategies. Another questionnaire study exam-
ined attitudes toward HPV vaccination among
378 German men, finding that approximately 74% of
these men wanted to be inoculated with the vaccine.16
A questionnaire study of 14–24-year-old boys and
men in Italy found that 58.2% of nonvaccinated par-
ticipants were willing to receive the vaccine.12 How-
ever, in our study, only 26% of male participants
responded that they thought that boys and men
should be vaccinated (Table 5). There may be differ-
ences in the survey methods used, but the awareness
of men in Japan regarding HPV prevention was esti-
mated to be extremely low, compared with that of
men in Western countries. A Korean questionnaire
study showed that only 25.1% of men wanted to
receive the HPV vaccine.17 Korea and Japan have
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similar problems regarding their HPV vaccination
programs.
Although the national HPV vaccination program in
Japan is almost at a standstill at present4 because of
the ongoing discussion of adverse events by the
MHLW, the willingness of the general population to
undergo HPV vaccination was relatively high, at
about 41% in the total sample (Table 5). This finding
is contrary to our estimation before the study. The
data clearly showed that a certain number of people
understand the importance of the HPV vaccine. How-
ever, we also revealed that the female laypersons
showed significantly more negative attitudes toward
inoculating their daughters with the HPV vaccine
than did male laypersons (aOR = 0.78, P = 0.006). In
contrast, these women showed a more positive atti-
tude than did their male counterparts toward the
inoculation of men and boys (aOR = 1.93, P < 0.001).
Because women knew more about adverse events fol-
lowing HPV vaccination than did men, they seemed
to think the vaccine was dangerous for their daugh-
ters, despite understanding its necessity. However,
they might have expressed mixed feelings, in that
they did not want their daughters to be infected with
HPV from men.
It has been reported that knowledge and awareness
alone do not lead people to take actual action in terms
of self-change processes.18 In self-change processes,
raising awareness and taking action are different
steps, and the approach for each step should be dis-
tinguished. Social marketing strategies are considered
an effective means of public health intervention.19
Applying these concepts to HPV vaccination pro-
grams is essential for eliminating nonscientific con-
cerns about adverse events and making people realize
the necessity of HPV vaccination, as part of the aim of
normalizing the HPV vaccine program in Japan.
Japan has a successful history of health promotion
using social marketing strategies to increase the recog-
nition of metabolic syndrome to over 95% among
men,20 thereby reducing mortality from cardiovascu-
lar diseases. Combining these approaches and our
results, we strongly appeal to both academic societies
and the government to implement a broad awareness
campaign to help Japanese citizens understand the
risks of HPV infection and related diseases. Such cam-
paigns should target not only girls and women, but
also boys and men, from early adolescence to
adulthood.
This study has several limitations regarding the
method of the questionnaire. First, the study was
conducted using a questionnaire created especially for
this research, and therefore it is difficult to objectively
assess each question’s correct answer rate compared
with other study data. It might have been advanta-
geous to perform a pilot study using a questionnaire
with standardized content before moving on to large-
scale studies. Another limitation is selection bias, in
that the participants might have had more interest in
health promotion, HPV, or CC, compared with the
general population, despite the fact that the question-
naire was administered to members of the general
population and those in nonmedical professions as
much as possible. Furthermore, conducting the survey
in the limited places and on the limited occasions cho-
sen by the researchers may also have led to
selection bias.
In keeping with the recommendations of the Cen-
ters for Disease Control and Prevention21 and the
Advisory Committee on Immunization Practices,22
vaccination of both sexes is already becoming a global
standard.23,24 Considering the importance of the effec-
tive prevention of HPV infection not only in Japan
but also in other countries with low HPV vaccination
coverage, as well as problems concerning adverse
events, male involvement is indispensable to chang-
ing the situation. In Ireland, a country whose HPV
vaccination crisis is similar to Japan, a nationwide
media campaign has led to improved vaccination
rates.25 We are planning to conduct a randomized
trial to examine how educational intervention can
change male attitudes toward HPV prevention.
In conclusion, the results of this large-scale ques-
tionnaire survey indicated that the general population
of men in Japan lacked knowledge and awareness of
HPV-related disease prevention as represented by CC
prevention. However, men generally showed more
positive attitudes toward HPV vaccination for their
daughters than did women. Increasing male involve-
ment in HPV prevention is an important step toward
achieving the goal of preventing HPV-related dis-
eases. Therefore, a new educational approach, irre-
spective of sex, to provide accurate information
including material on international circumstances is
urgently needed.
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